News & Events about Kura Oncology Inc.
Shares of Kura Oncology, Inc. (NASDAQ:KURA Get Rating) have earned a consensus recommendation of Moderate Buy from the six brokerages that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and five have issued a buy ...
Globe Newswire
3 months ago
SAN DIEGO, March 01, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is...
Globe Newswire
3 months ago
SAN DIEGO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2022 financial results ...
Globe Newswire
3 months ago
Phase 1 trial showed 30% CR rate among 20 NPM1-mutant AML patients treated at recommended Phase 2 dose Phase 2 registration-directed trial expected to enroll 85 patients in the U.S. and Europe SAN DIEGO, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage ...
Ticker Report
3 months ago
Kura Oncology, Inc. (NASDAQ:KURA Get Rating) has been assigned a consensus recommendation of Moderate Buy from the seven analysts that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and six ...